ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas
- 9 November 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (8) , 5165-5172
Abstract
Purpose The oncologic outcomes for atypical meningiomas can be poor. Generally, patients that have had a prior recurrence have a substantially elevated risk of a future recurrence. Additionally, certain tumor genomic profiles have been shown as markers of poor prognosis. We sought to characterize the genomic differences between primary and recurrent tumors as well as assess if those differences had implications on recurrence. Methods We identified primary and recurrent gross totally resected WHO grade II meningiomas with > 30 days of post-surgical follow-up at our institution. For genes with a prevalence of > 5% in the cohort, we compared the mutational prevalence in primary and recurrent tumors. For a gene of interest, we assessed the time to radiographic recurrence using adjusted cox-regression. Results We identified 88 meningiomas (77 primary, 16 recurrent) with a median follow-up of 5.33 years. Mutations in ARID1A found in association with recurrent tumors (7/16 recurrent tumors vs 5/72 primary tumors, p < 0.001). In the whole cohort, mutations in ARID1A were not associated with alterations in time to recurrence after adjusting for recurrence status (p = 0.713). When restricted to primary tumors, ARID1A is associated with a 625% increase in the hazard of recurrence (HR = 7.26 [1.42–37.0]; p = 0.017). Conclusion We demonstrate mutations in ARID1A, a chromatin remodeling gene, in a higher prevalence in recurrent tumors. We further demonstrate that when mutations in ARID1A are present in primary atypical meningiomas, these tumors tend to have worse prognosis. Further prospective study may validate ARID1A as a prognostic marker.Keywords
This publication has 31 references indexed in Scilit:
- Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomesJournal of Neurosurgery, 2016
- TERT Promoter Mutations and Risk of Recurrence in MeningiomaJNCI: Journal of the National Cancer Institute, 2015
- Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysisOncotarget, 2015
- ARID1A and TERT promoter mutations in dedifferentiated meningiomaCancer Genetics, 2015
- Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma developmentVirchows Archiv, 2014
- Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibitionOncotarget, 2014
- ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian CarcinomasInternational Journal of Molecular Sciences, 2013
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?Cancer Discovery, 2013
- Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastomaNature Genetics, 2012